Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.48 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481974 | 0.79 | FFAR1 (0.47) | FFAR1FFAR4TACR1 | |
| SCHEMBL6475327 | 0.75 | TACR1 (0.47) | FFAR1FFAR4TACR1 | |
| SCHEMBL27183028 | 0.73 | MAPT (0.63) | FFAR1GAAMAPTGFERSPHK1 | |
| SCHEMBL8871794 | 0.70 | TACR1 (0.50) | FFAR1FFAR4TACR1 | |
| SCHEMBL6476541 | 0.69 | MCL1 (0.53) | C5AR1 | |
| SCHEMBL9762664 | 0.69 | SIGMAR1 (0.49) | SPHK1 | |
| SCHEMBL8867308 | 0.69 | PEPD (0.55) | GAAMAPTGFER | |
| SCHEMBL4281427 | 0.68 | MAPT (0.70) | GAAMAPTGFER | |
| SCHEMBL336977 | 0.68 | TACR1 (0.62) | FFAR1FFAR4TACR1 | |
| SCHEMBL28874743 | 0.68 | KMT2A (0.51) | FFAR1FFAR4TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930131-B2 | Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) | WYETH (US) | 2005-08-16 | — | — | US | disclosed |
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | GPR119, INSR, SLC5A1 | FFAR1 31/4885FFAR4 22/4885C5AR1 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.